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Modafinil (2-[(diphenylmethyl) sulfinyl]
acetamide; United States brand name Provigil) is a wake-promoting agent first prescribed in France to treat narcolepsyassociated somnolence in the 1990s. Modafinil is currently prescribed in the United States for narcolepsy-associated somnolence, shift-work sleep disorder, and obstructive sleep apnea syndrome (Minzenberg and Carter, 2008) , and it is being investigated for treating cognitive dysfunction in schizophrenia, depression, and attention deficit hyperactivity disorder (Minzenberg and Carter, 2008) . Modafinil is considered safe, because subjects taking modafinil do not experience amphetamine-like withdrawal symptoms during discontinuation. Side effects of modafinil have been observed, however, including anxiety (4%), depression (4%), dyskinesia (2%), and psychosis [1 case (Wu et al., 2008)] . Understanding the precise mechanism(s) of action for modafinil may enable the development of more selective compounds having fewer side effects.
Studies performed in vivo and in vitro have suggested several possible mechanisms for the action of modafinil, including inhibiting dopamine and norepinephrine transporters and increasing dopamine, serotonin, glutamate, and histamine release (Minzenberg and Carter, 2008) . While it was suggested that effective doses of modafinil are insufficient to inhibit the dopamine transporter (DAT) and hence do not act via this mechanism (Mignot et al., 1994) , a recent positron emission tomography study in monkeys indicated 50% binding of modafinil to the DAT at lower plasma concentrations than are induced by therapeutic doses (Madras et al., 2006) . Moreover, mice lacking the DAT do not exhibit modafinil-induced wakefulness (Wisor et al., 2001) . DAT knock-out (KO) mice exhibit altered dopamine D 1 and D 2 receptors, however, as well as other compensatory mechanisms such as norepinephrine abnormalities. Thus, the mechanism of modafinilinduced wakefulness requires further investigation. Qu et al. (2008) combined pharmacological and genetic techniques to investigate the contribution of D 1 and D 2 receptors to modafinil-induced wakefulness. The authors used male D 2 receptor KO mice, as well as the D 1 -and D 2 -family antagonists SCH23390 and raclopride, respectively, to investigate possible dopaminergic mechanisms for modafinilinduced wakefulness. Mice were equipped with EEG and electromyogram electrodes in the cortex and both trapezius muscles respectively for polysomnographic recordings. Sleep-wakefulness states were recorded for 48 h, comparing baseline and experimental days. Polygraphic recordings were scored by 10 s epochs as wakefulness, rapid-eye-movement (REM), and non-REM (NREM) sleep according to published criteria.
The authors first demonstrated a longlasting, dose-dependent increase in wakefulness after modafinil administration [Qu et al. (2008) While this combined genetic and pharmacological approach provides striking evidence for D 2 receptor and D 1 family involvement in modafinil-induced increases in wakefulness, further evidence may be required. For example, the authors' interpretation of SCH23390-and raclopride-induced attenuation of modafinil-induced increase in wakefulness may be premature. Although the pharmacological evidence was compelling, the authors did not demonstrate whether the SCH23390 or raclopride reduction in modafinil-induced wakefulness was an additive or competitive effect, as they did not examine the effects of these drugs alone on wakefulness. Previous reports suggest that SCH23390 reduces wakefulness in rats by increasing REM and NREM sleep (Ongini et al., 1993) , while the D 2 antagonist increases sleep time in mice (Cohen et al., 1997) , opposite to the effects of modafinil in mice reported by Qu et al. (2008) . Thus, it cannot be concluded that the opposing effects of SCH23390 and raclopride on modafinilinduced wakefulness are not a result of competing orthogonal systems.
In addition, the authors argued that modafinil acts directly at D 1 and D 2 receptors, despite reporting no binding data to support this theory. Alternatively, modafinil may increase extracellular dopamine via DAT inhibition (Madras et al., 2006) , with SCH23390 or raclopride blocking its effects on wakefulness by competitively blocking the availability of dopamine to activate these receptors. [
11 C]raclopride binding is reduced in sleep-deprived humans, putatively via competition with increased endogenous extracellular dopamine after sleep deprivation (Volkow et al., 2008) . Thus, mediation of modafinil-induced wakefulness via a D 1 /D 2 receptor as opposed to DAT requires further evidence.
The interpretation of D 1 -selective SCH23390 effects on modafinil-induced wakefulness must also be qualified. As discussed above, SCH23390 is not selective for the D 1 receptor, since it also binds to the D 5 receptor in mice and has behavioral effects in D1 KO mice (Centonze et al., 2003) at doses used in the study by Qu et al. (2008) . Thus, a role for the D 5 receptor cannot be discounted. The reduced effects of modafinil on D 2 receptor KO mice provide evidence that the observed raclopride effects were likely to have been mediated by the D 2 receptor. Thus, greater evidence for a D 1 receptor involvement for modafinil-induced increases in wakefulness could be generated by assessing the effects of modafinil in D 1 KO mice, in combination with raclopride. These data would provide evidence similar to that generated by D 2 KO mice and strengthen the argument for D 1 receptor selectivity in the effects of modafinil. These findings would be particularly important given the interaction of D 5 receptors with ADHD, their localization on cholinergic neurons that are important for attentional performance, and the putative attentionenhancing effects of modafinil (Minzenberg and Carter, 2008) . It would also be informative to administer raclopride in efficacious (high)-dose modafinilpretreated D 2 KO mice, to further demonstrate D 2 selectivity of raclopride.
Modafinil does not induce wakefulness in mice lacking the DAT (Wisor et al., 2001) . Qu et al. (2008) caution against the interpretation that the DAT is therefore required for modafinil-induced wakefulness because DAT KO mice exhibit abnormal D 1 and D 2 receptor regulation, which may mediate the reduced efficacy of modafinil in these mice. Moreover, Qu et al. (2008) indicate that the nomifensineand modafinil-evoked current-voltage relationships differ on rat brain slices (Korotkova et al., 2007) , suggesting a different mechanism of action than DAT selectivity. Nomifensine is, however, threefold to fourfold more selective to the norepinephrine transporter than DAT (Tatsumi et al., 1997) , while modafinil binds threefold to fourfold more selectively to the DAT at clinically relevant doses (Madras et al., 2006) . GBR12909 is also more selective to the DAT, exhibits a similar behavioral profile to modafinil, and was also ineffective in DAT KO mice (Wisor et al., 2001) , suggesting that modafinil-induced DAT inhibition remains a viable hypothesis for the effects of modafinil. Moreover, the reduced effectiveness of modafinil in D 2 KO mice observed in the study by Qu et al. (2008) , could be interpreted as a result of the 50% reduction in functional DAT levels in these mice (Dickinson et al., 1999) .
The pharmacological studies by Qu et al. (2008) provide support for D 1 and D 2 receptor family involvement in wakefulness in mice. Moreover, the authors' combined genetic and pharmacological study provides evidence that the D 2 receptor is important in the arousal effects of modafinil. The authors' approach to investigating the mechanism of modafinilinduced wakefulness is an effective way to selectively examine receptor contributions to this effect. This approach could therefore be used to investigate the mechanism of modafinil-induced effects in other areas, such as locomotor activity or cognitive performance as these behaviors may be mediated by distinct mechanisms (Minzenberg and Carter, 2008) . Increased knowledge of the mechanisms of the effects of modafinil may allow increasing selectivity for these effects, or the generation of drugs with reduced side effects. Furthermore, Qu et al. (2008) provide thoughtful and incisive interpretations of genetic and pharmacological manipulations when using this combined genetic and pharmacological approach. Care must therefore be taken when interpreting the need for both the D 1 and D 2 receptors in mediating the modafinil-induced increases in wakefulness. D 5 receptor contributions to modafinil-induced wakefulness cannot as yet be discounted, nor can the contribution of the DAT. However, the study by Qu et al. (2008) provides a platform from which the contributions of these receptors can be further investigated.
